NMC
OVID icon

Nine Masts Capital’s Ovid Therapeutics OVID Stock Holding History

Nine Masts Capital’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,960
Closed -$22.8K – 294
2025
Q4 		$22.8K Buy
+13,960
New +$21.5K ﹤0.01% 98

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Nine Masts Capital's OVID Position: Q1 2026 in Review

Nine Masts Capital sold out of Ovid Therapeutics (OVID) in Q1 2026, closing a stake of 13,960 shares — an estimated $22.8K sold.

Nine Masts Capital first reported a position in OVID in Q4 2025 and held it in 1 quarter. The position peaked at $22.8K in Q4 2025. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Nine Masts Capital reported no remaining Ovid Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Nine Masts Capital sold 13,960 Ovid Therapeutics shares in Q1 2026, an estimated $22.8K.
  • Nine Masts Capital first reported a position in Ovid Therapeutics in Q4 2025 and held it in 1 quarter.
  • Nine Masts Capital's Ovid Therapeutics position peaked at $22.8K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.